Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep 1;2(9):e25736.
doi: 10.4161/onci.25736. Epub 2013 Jul 23.

Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer

Alexandr V Bazhin  1 , Jagadeesh Bayry, Viktor Umansky, Jens Werner, Svetlana Karakhanova
Affiliations

Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer

Alexandr V Bazhin et al. Oncoimmunology. .

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of malignancy. Via a broad stimulation of the immune system, PDAC activates both antitumor immune responses and immunosuppressive mechanisms. We propose that new immunotherapeutic strategies for the management of PDAC should be designed to specifically neutralize the immunosuppressive tumor microenvironment.

Keywords: immunosuppression; immunotherapy; pancreatic cancer; regulatory T cells.

PubMed Disclaimer

Figures

None
Figure 1. Double immunological consequences of pancreatic ductal adenocarcinoma. Pancreatic ductal adenocarcinoma (PDAC) cells expressing tumor-associated antigens (A) activate the immune system in PDAC patients (B). This generally results in the elicitation of PDAC-specific immune responses (C). In addition, PDAC cells can activate the immunosuppressive arm of the immune system (D), thus damping antitumor immune responses (E).
See this image and copyright information in PMC

References

    1. Cress RD, Yin D, Clarke L, Bold R, Holly EA. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States) Cancer Causes Control. 2006;17:403–9. doi: 10.1007/s10552-005-0539-4. - DOI - PubMed
    1. Rosty C, Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am. 2002;16:37–52. doi: 10.1016/S0889-8588(01)00007-7. - DOI - PubMed
    1. Ryschich E, Nötzel T, Hinz U, Autschbach F, Ferguson J, Simon I, et al. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma. Clin Cancer Res. 2005;11:498–504. - PubMed
    1. Heller A, Zörnig I, Müller T, Giorgadze K, Frei C, Giese T, et al. Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer. Cancer Immunol Immunother. 2010;59:1389–400. doi: 10.1007/s00262-010-0870-9. - DOI - PMC - PubMed
    1. Schmidt J, Jäger D, Hoffmann K, Büchler MW, Märten A. Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring. J Immunother. 2007;30:108–15. doi: 10.1097/01.cji.0000211317.15278.27. - DOI - PubMed

LinkOut - more resources